Clinical trials: ST-Elevation Myocardial Infarction
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Post Procedural Myocardial Infarction
Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
This study investigates the cardioprotective effect of remote ischaemic pre-/postconditioning in patients presenting with a NSTEMI/Unstable angina undergoing PCI.
- Trial name
- NCT03726164
- Testing
- Remote Conditioning
- Volunteers
- 626 people
- Sponsor
- University College, London
STEMI, NSTEMI
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and…
- Trial name
- NCT05175261
- Testing
- Prolocor pFCG test
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Prolocor, Inc
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
AMI
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and…
- Trial name
- INTENSIVE (NCT00670228)
- Testing
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Where
- 5 sites in United States, Argentina and 3 more
- Volunteers
- 34 people
- Sponsor
- Sanofi
Cardiac Arrest Due to Underlying Cardiac Condition, Ventricular Fibrillation
ACCESS to the Cardiac Cath Lab in Patients Without STEMI Resuscitated From Out-of-hospital VT/VF Cardiac Arrest
To determine if survival to hospital discharge with good neurological outcome for adults ages 18-75 who are resuscitated from out-of-hospital VT/VF cardiac arrest without clinical signs of a heart attack do better by going…
- Conditions
- Cardiac Arrest Due to Underlying Cardiac Condition, Ventricular Fibrillation, Cardiopulmonary Arrest With Successful Resuscitation
- Trial name
- NCT03119571
- Testing
- Initial CCL admission, Initial ICU admission
- Where
- 23 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- University of Minnesota
Coronary Artery Disease, Coronary Stenosis
ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)
The objective of this prospective, single-blind clinical investigation is to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent…
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, STEMI
- Trial name
- NCT03507777
- Testing
- Coronary PCI guided by OCT, Coronary PCI guided by Angiography
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 2,487 people
- Sponsor
- Abbott Medical Devices
Infarction, Myocardial
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Multinational, multicentre, randomised, prospective, open, parallel group study directly comparing two glycoprotein-IIb/IIIa inhibitors, abciximab and eptifibatide, added early to standard treatment before primary PCI of STEMI…
- Trial name
- NCT00426751
- Testing
- Abciximab, Eptifibatide
- Where
- 24 sites in France, Germany
- Volunteers
- 429 people
- Sponsor
- GlaxoSmithKline
Cardiogenic Shock, Acute Myocardial Infarction
National Cardiogenic Shock Initiative
This study evaluates the use of early mechanical circulatory support in patients presenting with acute myocardial infarction and cardiogenic shock.
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCSI (NCT03677180)
- Where
- 75 sites in United States
- Volunteers
- 406 people
- Sponsor
- Henry Ford Health System
Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation
Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction
The aim of the study is to prove that early discharge (within 72 hours) in selected group of patients after myocardial infarction with elevations of ST-segment is feasible and safe
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation, Primary Percutaneous Coronary Intervention, Early Discharge
- Trial name
- NCT02023983
- Testing
- Early discharge, Standard discharge
- Where
- Czechia
- Volunteers
- 151 people
- Sponsor
- Kamil Novobílský
STEMI
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
The primary objective of this study is to assess whether an aggressive quality improvement intervention strategy will decrease time from hospital presentation to first balloon inflation in non-transfer patients with acute ST…
- Trial name
- RAPID-PCI (NCT01625104)
- Testing
- Non Intervention, Agressive Intervention Process Improvement Strategies
- Where
- United States
- Volunteers
- 882 people
- Sponsor
- University of Michigan
Myocardial Infarction, Multivessel Coronary Artery Disease
Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.
The Compare-Acute trial is a prospective randomised trial in patients with multivessel disease, who are admitted into hospital with a ST-elevation Myocardial Infarction.
- Trial name
- CompareAcute (NCT01399736)
- Testing
- FFR-guided revascularisation strategy, randomised to guidelines group
- Where
- 26 sites in Czechia, Germany and 6 more
- Volunteers
- 885 people
- Sponsor
- Maasstad Hospital
Acute Myocardial Infarction
Bivalirudin Infusion for Ventricular Infarction Limitation
The purpose of this study is to evaluate whether the use of bivalirudin will reduce extent of the damage done to the heart muscle in participants who suffered a heart attack, compared to the comparator treatment (heparin).
- Trial name
- BIVAL (NCT02565147)
- Testing
- PPCI, Bivalirudin, Heparin
- Where
- 4 sites in France, Netherlands
- Volunteers
- 78 people
- Sponsor
- The Medicines Company
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Myocardial Infarction, Death
Relation Between NLR and IMR in STEMI Patients
The neutrophil-to-lymphocyte ratio (NLR) has been proven to be reliable inflammatory marker for atherosclerotic process and predictor for clinical outcomes in patients with various cardiovascular diseases.
- Trial name
- NCT02828137
- Volunteers
- 123 people
- Sponsor
- Inha University Hospital
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Non ST Elevation Myocardial Infarction
Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up
1. INTRODUCTION Through last couple of years the number of patients treated for acute coronary event without persistent ST segment elevation in ECG has been growing.
- Trial name
- NCT01863134
- Testing
- Eptifibatide
- Where
- 6 sites in United States, Poland
- Volunteers
- 140 people
- Sponsor
- Medical University of Silesia
Myocardial Infarction
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients…
- Trial name
- NCT00433966
- Testing
- Bivalirudin, Unfractionated heparin, Bare metal stent
- Where
- United States
- Volunteers
- 3,602 people
- Sponsor
- Cardiovascular Research Foundation, New York
Acute Coronary Syndrome
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is…
- Trial name
- TRILOGY ACS (NCT00699998)
- Testing
- Clopidogrel, Prasugrel, Commercially-available Aspirin
- Where
- 688 sites in United States, Argentina and 51 more
- Volunteers
- 9,326 people
- Sponsor
- Eli Lilly and Company